CAR-T market poised for immense growth over next decade

The market for revolutionary CAR-T cancer treatments is expected to grow to USD 14 billion by 2030, according to new research.

The market for revolutionary CAR-T cancer treatments is expected to grow to USD 14 billion by 2030, according to new research.

Figures published by research firm Roots Analysis forecast the sector to grow at a compound annualised rate of 28% over the next nine years.

Roots’ analysis attributed this growth to CAR-T therapies’ ability to direct the human immune system to attack cancer cells, leading to prolonged remission periods.

“Several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status,” the company added.

The report noted that at least four CAR-T therapies have already been approved for use, with many more viable candidates currently under evaluation.

“The CAR-T cell therapy market is characterized by a healthy and growing pipeline,” the research noted.

“Further, with lucrative financial support and notable increase in partnerships, the CAR-T-cell therapies market is abuzz with activity.

Current generation CAR-T treatments remain costly

While CAR-T represents a breakthrough in the treatment of several B-cell cancer types, new research from Prime Therapeutics shows the current generation of treatments for B-cell lymphoma cost an average of US $700,000.

While the actual wholesale cost of the drugs used during this treatment only cost an average US $373,000, this amount swells by a further US $300,000 plus when factoring in post-treatment care.

In 12% of cases, the total cost of current generation B-cell lymphoma CAR-T and post-treatment care, including drugs and other costs, totalled US $1 million or more.

A handful of companies, including the Australian-listed Prescient Therapeutics (ASX: PTX), are now developing the next generation of these treatments with a view to making them safer and – notably – more affordable for patients.

To stay up-to-date on Prescient Therapeutics’ news and announcements, register your details at their investor centre.


Reach Markets have been engaged by PTX to help manage their investor communications.




This Week’s News


8 May 2024

BHP Xplor winner coming to the ASX


16 April 2024

Gold at record highs – so why aren’t gold stocks?


22 November 2023

Rare Earths Industry Review: Part 2

General Advice Warning

Any advice provided by Reach Markets including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. If you are thinking about acquiring a financial product, you should consider our Financial Services Guide (FSG)

including the Privacy Statement and any relevant Product Disclosure Statement or Prospectus (if one is available) to understand the features, risks and returns associated with the investment.

Please click here to read our full warning.